-+ 0.00%
-+ 0.00%
-+ 0.00%

NIAGEN BIOSCIENCE RECEIVES EXCLUSIVE U.S. FDA RARE PEDIATRIC DISEASE (RPD) DESIGNATION AND EUROPEAN MEDICINES AGENCY ORPHAN MEDICINAL PRODUCT DESIGNATION (OMPD) FOR NB4168 FOR THE TREATMENT OF ATAXIA TELANGIECTASIA (A-T)

Reuters·07/13/2026 12:32:00

Please log in to view news